We recently announced positive interim results from an open-label, Phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis (see press release here). On April 28th, I also...
Read More Pulmonary Arterial Hypertension is Associated with Elevated Levels of Galectin-3 and a Potential Therapeutic Target for GR-MD-02
1 Comments , in Article
Elevated levels of the Galectin-3 protein are associated with multiple disease processes, in addition to those Galectin Therapeutics is addressing in ongoing clinical trials such as fatty liver disease, psoriasis...
Read More
By Peter G. Traber, M.D. on April 28, 2016 Last September, Galectin Therapeutics began a Phase 2a open-label clinical trial with GR-MD-02, our galectin-3 inhibitor drug, in patients with moderate-to-severe...
Read More
By Peter G. Traber, M.D. on March 17, 2016 We often talk about how Galectin Therapeutics’ proprietary compound, GR-MD-02, is protected by a strong intellectual property portfolio. I thought it...
Read More
By Galectin Therapeutics. on January 7, 2016 The many accomplishments at Galectin Therapeutics during 2015 ranged from incremental progress touching every aspect of our business to significant advancements with GR-MD-02. Importantly,...
Read More Two Clinical Trials Using GR-MD-02 Galectin-3 Inhibitor in Combination with Cancer Immunotherapy Drugs
0 Comments , in Article
By Peter G. Traber, M.D. on November 12, 2015 The galectin-3 protein appears to play an important role in the progression of many cancers, especially with respect to the ability...
Read More
By Peter G. Traber, M.D. on October 21, 2015 Bristol-Myers Squibb ($BMS) recently paid $150 million for the exclusive right to acquire Promedior, a clinical-stage biotechnology company in the midst...
Read More
By Peter G. Traber, M.D. on October 15, 2015 When thinking about the development of a drug, one naturally tends to think of performing animal and human studies to demonstrate...
Read More
Written by Peter G. Traber, M.D. on September 24, 2015 Serendipity, or fortunate happenstance, has always been an important part of the search for medicines. As pointed out by Thomas...
Read More
Written by Peter G. Traber, M.D. on September 9, 2015 An important question in drug development, and the subject of U.S. Food and Drug Administration (FDA) regulations, is whether a...
Read More